Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
| ▸ | PNP | P00491 | 4/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490343 | 0.88 | ADORA3 (0.46) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL4370992 | 0.88 | ADORA3 (0.46) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL30612742 | 0.83 | ADORA3 (0.42) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL30697779 | 0.81 | TK1 (0.46) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL3514475 | 0.81 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL29905570 | 0.80 | ADORA3 (0.44) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL5999293 | 0.79 | PNP (0.43) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL8104279 | 0.79 | PNP (0.47) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL8490899 | 0.78 | ADORA3 (0.48) | ADORA3TK1PNPBLMUSP2 | |
| SCHEMBL4409632 | 0.78 | TK1 (0.44) | ADORA3TK1PNPBLMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009517350-A | — | — | 2009-04-30 | — | — | JP | claimed |
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2009-01-15 | — | — | US | claimed |
| EP-1973571-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-10-01 | — | — | EP | claimed |
| WO-2007059931-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2007-05-31 | — | — | WO | claimed |
| CN-113396219-B | Purification of mRNA by tangential flow filtration | ETHRIS GMBH (DE) | 2026-05-26 | — | — | CN | disclosed |
| CN-120129532-A | Stabilized lipid or lipid nanoparticle suspensions | 埃泽瑞斯公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4504970-A1 | COMPOSITIONS AND ANALYSIS OF DEPHOSPHORYLATED OLIGORIBONUCLEOTIDES | New England Biolabs, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-113423418-B | Treatment of cilia disease | 埃泽瑞斯公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-112805386-B | Plasmid containing a sequence encoding mRNA having a segmented poly (A) tail | 埃泽瑞斯公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118949075-A | Treatment of cilia disease | 埃泽瑞斯公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024042236-A1 | STABLE LIPID OR LIPIDOID NANOPARTICLE SUSPENSIONS | ETHRIS GMBH (DE) | 2024-02-29 | — | — | WO | disclosed |
| EP-4297722-A1 | FORMULATIONS FOR AEROSOL FORMATION AND AEROSOLS FOR THE DELIVERY OF NUCLEIC ACID | Ethris GmbH (DE) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023197015-A1 | COMPOSITIONS AND ANALYSIS OF DEPHOSPHORYLATED OLIGORIBONUCLEOTIDES | NEW ENGLAND BIOLABS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-8119689-B2 | Adjuvants on the basis of bisacyloxypropylcystene conjugates and derivatives and their uses in pharmaceutical compositions | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-1973571-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007059931-A1 | NEW ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTEINE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090017106-A1 | ADJUVANTS ON THE BASIS OF BISACYLOXYPROPYLCYSTENE CONJUGATES AND DERIVATIVES AND THEIR USES IN PHARMACEUTICAL COMPOSITIONS | CYSLTR2, CYSLTR1, GSTO1 | ADORA3 941/4885TK1 2217/4885PNP 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.